BOULDER, Colo., Feb. 28 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. announced today that it will report its fourth quarter and year-end 2006 financial results on March 6, 2007, before the U.S. financial markets open. Management will provide a company update and discuss the fourth quarter and full year 2006 results during a conference call on Tuesday, March 6, 2007 at 9:00 a.m. Eastern Time (7:00 a.m. Mountain Time).
To participate in the conference call, please dial 866.825.3354 (domestic) or 617.213.8063 (international) and reference the access code 67643132. A replay of the call will be available from 11:00 a.m. Eastern Time on March 6, 2007 until March 13, 2007 at midnight Eastern Time. To access the replay, please dial 888.286.8010 (domestic) or 617-801-6888 (international) and reference the access code 56588359. A live audio webcast of the call will also be available on the “Investors” section of the Company’s website, www.tapestrypharma.com. An archived webcast will be available on the Tapestry website for approximately 30 days after the event.
About Tapestry Pharmaceuticals, Inc.
Tapestry Pharmaceuticals, Inc. is a company focused on the development of proprietary therapies for the treatment of cancer.
For more information about Tapestry and its technologies, visit Tapestry’s web site at www.tapestrypharma.com.
Contact: Tapestry Pharmaceuticals, Inc. Gordon Link Senior Vice President, Chief Financial Officer 303-516-8500 glink@tapestrypharma.com Elma Hawkins, PhD Communications and Corporate Development 212-400-3019 ehawkins@tapestrypharma.com Investor: Lilian Stern Stern Investor Relations, Inc. 212-362-1200 lilian@sternir.com Media: Dana Conti Schwartz Communications, Inc. 781-684-0770 tapestry@schwartz-pr.com
Tapestry Pharmaceuticals, Inc.
CONTACT: Gordon Link, Senior Vice President, Chief Financial Officer,+1-303-516-8500, or glink@tapestrypharma.com, or Elma Hawkins, PhD,Communications and Corporate Development, +1-212-400-3019, orehawkins@tapestrypharma.com, both of Tapestry Pharmaceuticals, Inc.; orInvestors, Lilian Stern of Stern Investor Relations, Inc., +1-212-362-1200,or lilian@sternir.com; or Media, Dana Conti of Schwartz Communications,Inc., +1-781-684-0770, or tapestry@schwartz-pr.com
Web site: http://www.tapestrypharma.com/
